This is an identity reference. It describes what the name BPC-157 refers to, how to confirm you have the compound you intend, and how its structure affects its analysis. It says nothing about what the compound does, and it is not guidance on preparation, handling or use.
What the name refers to
BPC-157 is a synthetic pentadecapeptide — fifteen amino acid residues — with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, written in single-letter code as GEPPPGKPADDAGLV. The designation derives from “body protection compound” in the original literature; the number is a laboratory designation rather than a systematic chemical identifier.
It is a linear peptide with no disulfide bridges and no cyclisation, composed entirely of standard proteinogenic L-amino acids. That last point is worth noting because many peptides in this catalogue category contain non-natural residues; BPC-157 does not.
Structural features that matter analytically
Four prolines out of fifteen residues. A high proline content is unusual and has real consequences for chromatography. Proline’s cyclic side chain restricts backbone conformation and enables cis–trans isomerisation about the peptide bond preceding it. Peptides with several prolines can show broadened or shouldered peaks under reverse-phase conditions simply from conformational exchange — not because the material is impure, but because different conformers travel slightly differently. Column temperature control matters more for sequences like this than for most.
No aromatic residues. There is no tryptophan, tyrosine or phenylalanine in the sequence. This has a direct practical consequence: BPC-157 absorbs weakly at 280 nm. Any purity figure quoted at that wavelength should be treated with caution, and analysis at 214 nm — where the backbone amide absorbs — is the appropriate method. It also means UV quantification using an extinction coefficient derived from aromatic residues is not available for this compound.
Charge profile. One lysine and one N-terminal amine as basic sites; one glutamate and two aspartates as acidic. The basic sites are where trifluoroacetate counter-ions associate after reverse-phase purification, which contributes mass to the lyophilised powder without contributing peptide. Net peptide content and counter-ion form therefore both belong in any calculation of molarity.
Nomenclature and near-neighbours
The catalogue also lists blends containing BPC-157 alongside other compounds. A blend is a different product from the single compound and carries a different total mass and a different analysis. Read the full product name rather than matching on the first token — this is the most common ordering error we see in this part of the catalogue.
Confirming identity independently
The sequence above can be checked against public chemical databases, and our product pages carry compound identity links that run those searches directly. Independent confirmation from a source with no commercial interest in the answer is worth more than any supplier’s assertion, including ours.
What we publish
BPC-157 in our catalogue sits under extracellular matrix and cell-migration peptides, a grouping by the pathway the compound is studied against rather than by any intended outcome. The product page carries an independent reverse-phase HPLC analysis, net peptide content, counter-ion form and vial size. Our vials carry no batch or lot numbers; a vial is matched to its published test by crimp and cap colour.
Research use only. All products supplied by Battle Born Peptides are laboratory reference materials for in-vitro research and analytical use by qualified professionals. They are not drugs, foods, dietary supplements, cosmetics or medical devices; they are not approved by the FDA or any other regulator for use in humans or animals; and they are not intended to diagnose, treat, cure, mitigate or prevent any disease, or to affect the structure or any function of the body of humans or animals. Nothing in this article is preparation, handling or dosing guidance. See our full research-use terms.